DeOndra Dixon INCLUDE Project Act of 2025
Summary
HR3491 (DeOndra Dixon INCLUDE Project Act) authorizes a Down syndrome research program at NIH but appropriates zero funding. With only 5 procedural actions over a year and stalled committee markup, the bill has no near-term market impact. No public companies are directly affected.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Zero appropriated funds — authorization-only bill has no direct financial impact on companies
- 2.Stalled legislative velocity: 1-year gap between introduction and committee markup
- 3.No public companies named or financially linked; academic research institutions are the sole beneficiaries if funding materializes
Market Implications
No publicly traded companies have direct revenue exposure to this authorization-only bill. The research program would benefit academic grantees, not corporate entities. Investors should not adjust positions based on this legislation.
Full Analysis
The bill, introduced May 2025, authorizes the NIH Director to carry out the INCLUDE Project for Down syndrome research. Its status remains 'Reported out of committee — awaiting floor action' after a unanimous 46-0 committee vote on May 21, 2026. However, the bill explicitly does not appropriate any funds — it merely authorizes a program structure. No dollar amounts appear in the text, and the action history shows nearly a year elapsed between introduction and the single committee markup, indicating low legislative priority. Authorizations without appropriations have no binding effect on federal spending or private sector revenue. The research program, if eventually funded through separate appropriations, would flow through NIH grants to academic institutions and research hospitals, not directly to publicly traded companies. No pharmaceutical, biotech, or diagnostic company is named in the bill or its findings. Related bills (S891, HR1768) cover broader healthcare topics but lack specific Down syndrome funding mechanisms. With no market catalyst, no funding stream, and no named corporate beneficiaries, this bill registers as procedural noise for investors.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →